Adaptive works with over 175 biopharmaceutical partners in hundreds of trials per year across the research and development value chain to incorporate proven immune-driven metrics and screening capabilities into translational analyses, diagnostic tools and drug discovery efforts.
We work collaboratively to elucidate mechanism of action and dosing for earlier phase clinical trials, identify biomarkets of efficacy or adverse events for later stage trials, and for drug candidates that utilize or leverage the acumen of the immune system.
In all our partnering models, Adaptive provides end-to-end support including hypothesis-driven trial design, extensive data analyses, parallel regulatory support when necessary, compliant data transfer and novel target screening.
Our models range from fee-for-service to diagnostic partnering to data generation for discovery purposes.
Reach out and we can work with you on how our immune medicine platform can accelerate your drug discovery and development efforts.
We work collaboratively to elucidate mechanism of action and dosing for earlier phase clinical trials, identify biomarkers of efficacy or adverse events for later stage trials, and screen for drug candidates that utilize or leverage the acumen of the immune system. In all our partnering models, Adaptive provides end-to-end support including hypothesis-driven trial design, extensive data analyses, parallel regulatory support, compliant data transfers, and novel target screening.
Diagnostics (888) 552-8988 | Corporate (206) 659-0067 | Research (855) 466-8667
© Adaptive Biotechnologies. All Rights Reserved.
Privacy Policy | Cookie Policy | Do Not Sell My Info (CA Residents) | Terms of Service | Code of Conduct
Diagnostics (888) 552-8988
Research (855) 466-8667
Corporate (206) 659-0067
© Adaptive Biotechnologies. All Rights Reserved.